Successful Management of Patients Receiving Bispecific Antibodies for Hematologic Malignancies

Friday, November 15, 2024

3:45 PM – 4:45 PM CT

Location: Grapevine Ballroom

CE: 1.00 credits/hours

Speaker(s)

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA (she/her/hers)

Clinical Pharmacy Manager
The University of Kansas Cancer Center
Kansas City , Missouri, United States
Jill O'Brien, PA-C

Hematology/Oncology Physician Assistant
Cleveland Clinic

Disclosures:

Zahra Mahmoudjafari has served on advisory boards for Genmab, Janssen, and Sanofi, and as a consultant for Pfizer.
Jill O'Brien has no relevant financial relationships to disclose.

Learning Objectives:

Assess the differences regarding mechanism of action, dosing, and inpatient monitoring of each bispecific antibody utilized in the management of hematologic malignancies
Identify appropriate strategies to incorporate bispecific antibodies into the treatment of hematologic malignancies as recommended in current guidelines
Apply current evidence-based clinical practice approaches to improve patient outcomes with supportive care for patients receiving a bispecific antibody for the treatment of a hematologic malignancy